On April 13, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, reported that it has completed its preclinical development of a novel formulation containing cannabinoids which have demonstrated anti-tumor properties in studies held at the company’s High Throughput Screening (HTS) research facility in Israel, which were focused on gastrointestinal cancers (Press release, Cannabics Pharmaceuticals, APR 13, 2020, View Source [SID1234556270]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company plans to examine the clinical safety and efficacy of the novel formulation which contains high concentrations of the cannabinoids CBDV and CBGA in a proprietary formulation. These cannabinoids have demonstrated complex combinatorial anti-tumor effect and have no psychoactive effect which enables patients to be treated with high dosages without intoxication.

On April 13, 2020 Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, reported that it will release financial results for the year ended December 31, 2019 on Wednesday, April 15, 2020 (Press release, Medicure, APR 13, 2020, View Source [SID1234556269]). The financial statements will be made available on the Company’s website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Thursday, April 16, 2020 at 7:30 AM Central Time (8:30 AM Eastern Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Info:

Topic: Medicure’s Fiscal Year End 2019 Results

Call date: Thursday, April 16, 2020

Time: 7:30 AM Central Time (8:30 AM Eastern Time)

Canada toll: 1 (416) 764-8659

North American toll-free: 1 (888) 664-6392

Passcode: not required

Webcast: This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: View Source

You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company’s website.

On April 13, 2020 AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations, reported that it has scheduled a conference call to discuss its first quarter 2020 financial results on Monday, May 11, 2020 at 5:00 p.m. Eastern Time (Press release, AMN Healthcare Services, APR 13, 2020, View Source [SID1234556268]). The same day, the Company also expects to issue an earnings news release after market close at approximately 4:15 p.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the call can be accessed through AMN Healthcare’s website at View Source Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Interested parties may participate live via telephone by dialing (844) 721-7241 in the U.S., or (409) 207-6955 for international callers, and using participant code 4038932. Following the conclusion of the call, a replay of the webcast will be available at the Company’s website. Alternatively, a telephonic replay of the call will be available beginning at 7 p.m. Eastern Time on May 11, 2020, and can be accessed until 11:59 p.m. Eastern Time on May 25, 2020 by calling (866) 207-1041 in the U.S. or (402) 970-0847 internationally, with access code 1880818.

On April 13, 2020 Select Medical Holdings Corporation ("Select Medical") (NYSE: SEM), reported that it will release the financial results for its first quarter ended March 31, 2020 on Thursday, April 30, 2020 after the market closes (Press release, Select Medical, APR 13, 2020, View Source [SID1234556267]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Select Medical will host a conference call regarding its first quarter results, as well as the impact of the COVID-19 pandemic on each of its reporting segments, on Friday, May 1, 2020, at 9:00am ET. The domestic dial in number for the call is 1-866-440-2669. The international dial in number is 1-409-220-9844. The conference ID for the call is 2296334. The conference call will be webcast simultaneously and can be accessed at Select Medical Holdings Corporation’s website www.selectmedicalholdings.com.

For those unable to participate in the conference call, a replay will be available until 12:00pm ET, May 8, 2020. The replay number is 1-855-859-2056 (domestic) or 1-404-537-3406 (international). The conference ID for the replay will be 2296334. The replay can also be accessed at Select Medical Holdings Corporation’s website, www.selectmedicalholdings.com.

On April 13, 2020 Sutro Biopharma, Inc. (NASDAQ: STRO), reported that the company has been invited to present updated clinical data from its STRO-002 antibody-drug conjugate (ADC) at the upcoming AACR (Free AACR Whitepaper) Virtual Annual Meeting 2020 (Press release, Sutro Biopharma, APR 13, 2020, View Source [SID1234556266]). The submitted abstract and a virtual poster presentation, which will consist of further updated data accompanied by a video presentation from Dr. Wendel Naumann of The Levine Cancer Institute, will be available on demand on the AACR (Free AACR Whitepaper) website (aacr.org) on Monday, April 27. Additionally, Sutro will host a conference call and live audio webcast on Monday, April 27 to discuss the STRO-002 clinical data, details of the call will be provided within the next week.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper) presentation will include updated initial dose escalation safety and efficacy data from the company’s ongoing Phase I study of STRO-002 in ovarian and endometrial cancer. STRO-002 is a novel ADC targeting the clinically validated folate receptor-α (FolRα), an antigen known to be overexpressed in ovarian cancer. Sutro discovered and manufactures STRO-002 using its proprietary XpressCF+ cell-free protein synthesis technology.

Poster Presentation Details:

STRO-002-GM1, a First in Human, Phase 1 Study of STRO-002, an anti-Folate Receptor-alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC), including Fallopian Tube or Primary Peritoneal Cancers

Date: Monday, April 27, 2020

Abstract Number: 9807

The abstract title was published today on the AACR (Free AACR Whitepaper) website. The submitted abstract and the virtual poster presentation will be also accessible through the Clinical/Scientific Presentation and Publication Highlights page of the News section of the company’s website at www.sutrobio.com on the day of the poster presentation.